BioMarin Pharmaceutical Inc. Files 8-K
Ticker: BMRN · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: BMRN
TL;DR
BioMarin filed an 8-K on Oct 27, 2025, updating on financials. No major news yet.
AI Summary
On October 27, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with no specific new financial figures or material events detailed in the provided text.
Why It Matters
This filing indicates BioMarin Pharmaceutical Inc. is providing updates on its financial condition and operational results to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not disclose any new material risks or adverse events.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- October 27, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 68-0397820 (identifier) — I.R.S. Employer Identification No.
- 770 Lindaro Street San Rafael California 94901 (address) — Principal Executive Offices
- 415-506-6700 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by BioMarin Pharmaceutical Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to include Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on October 27, 2025.
What is BioMarin Pharmaceutical Inc.'s state of incorporation?
BioMarin Pharmaceutical Inc. is incorporated in Delaware.
What is the principal executive office address for BioMarin Pharmaceutical Inc.?
The principal executive office address is 770 Lindaro Street, San Rafael, California 94901.
Does this filing indicate any specific new product launches or regulatory approvals?
The provided text of the 8-K filing does not contain information about specific new product launches or regulatory approvals; it focuses on financial condition and results of operations.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-27 16:08:23
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market In
Filing Documents
- bmrn-20251027.htm (8-K) — 24KB
- earningsrelease-27oct25ex9.htm (EX-99.1) — 350KB
- imagea.jpg (GRAPHIC) — 194KB
- 0001048477-25-000104.txt ( ) — 784KB
- bmrn-20251027.xsd (EX-101.SCH) — 2KB
- bmrn-20251027_lab.xml (EX-101.LAB) — 21KB
- bmrn-20251027_pre.xml (EX-101.PRE) — 12KB
- bmrn-20251027_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 27, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2025. The Company's press release issued on October 27, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of the Company dated October 27, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: October 27, 2025 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer